Med Chem III
Med Chem III
Med Chem III
A4
DA
4
4D
Paper / Subject Code: 87611 / Medicinal Chemistry- III
BC
5F
D9
48
E7
A4
DA
CD
AB
4D
5F
D9
48
AB
B0
E7
A4
CD
AB
D
16
5F
D9
48
B
0
FC
A4
Time:3Hrs Marks:75
DA
D
B
AB
16
BC
7B
D9
Q.I. Answer the following Multiple Choice Questions. Select the most appropriate
8
B0
FC
B4
FB
DA
D
option for each statement. 20M
A
16
BC
B
9
A
25
DD
7
B0
C
B4
FB
DA
D4
BF
Sr No Questions Options
BC
A
5
74
C1
48
B7
2
1 Identify the following structure a Amoxicillin
A
D4
B
FE
BF
B
5F
D
16
b Ampicillin
0A
4
45
8
B7
2
7
FC
B4
c Cloxacillin
A
4
6B
FE
9A
5F
D
B
0A
d Penicillin V
1
5
DD
48
7
2
7
C
4
FB
D4
6B
FE
9A
BF
B
BC
0A
5
4
C1
45
DD
7
42
7
B
DA
6B
E
9A
F
4D
5F
C
5F
1
48
AB
7
2
E7
C
A4
B
CD
D4
B
AB
F
5F
D
5F
16
2 Hammett constant is a measure of a Lipophilicity of substituent
7B
9
4
48
DD
B0
2
E7
FC
4
FB
DA
b Log P of substituent
D4
9A
AB
16
7B
25
c Steric effect of substituent
4
45
8
D
B0
FC
7
4
FB
DA
CD
D4
E
9A
AB
5F
7B
25
74
-lactam ring in cephalosporin is fused
8
AB
D
3 a Dihydrothiazine ring
B0
FC
A4
4
FB
CD
D4
FE
B
8D
6
with
7B
9
A
25
C1
74
45
B
DD
0
B4
FB
b Dihydrothiazole ring
DA
D4
FE
9A
BF
16
BC
A
25
Dihydrothiadiazine ring
4
45
8
D
7
0
E7
4
B
DA
D4
CD
6B
9A
F
AB
d Dihydrothiadiazole ring
F
5F
B
25
4
48
AB
DD
7
C
A4
FB
D4
BF
AB
5F
8D
b 15 membered lactam ring
16
BC
D9
5
74
7
42
B0
FC
A4
DA
FE
4D
5F
16
B
D9
0A
d 14 membered lactam ring
45
AB
48
7
2
E7
C
B
CD
6B
9A
AB
4D
5F
8D
5F
C1
AB
DD
has a pka of
B7
2
B0
E7
A4
B4
D4
BF
5F
b 7.2-7.8
8D
BC
16
D9
0A
4
45
B7
2
7
FC
c 9.1-97
B4
DA
CD
6B
D4
E
9A
5F
5F
7B
A
d 5.5-6.5
C1
4
8
AB
DD
B0
42
7
4
B4
FB
6 a
A
4D
D
16
BC
9
A
25
5
as antimalarial agent is
48
DD
B0
FC
E7
4
A
D4
9A
AB
b dihydroartemisinin
8D
16
BC
F
7B
74
45
D
B0
FC
c Arteether
B4
FB
CD
FE
9A
8D
6
7B
d Artesunate
A
5
C1
45
B
D
42
B0
4
FB
9A
BF
D
16
A
25
b Linker-Drug-Carrier
8
DD
B7
B0
FC
B4
DA
D4
c Linker-Carrier-Drug
5F
16
BC
7B
0A
74
48
42
d Drug-Linker-Drug
FC
FB
DA
B
E
AB
4D
5F
16
48
0
E7
FC
A4
FB
b L-erythro isomer
D4
AB
5F
16
7B
25
c D-erythro isomer
74
B0
FC
A4
FB
D4
E
d D-Threo isomer
5F
16
B
D9
25
74
FB
CD
D4
E
9A
b Clindamycin
5F
7B
25
74
AB
DD
c Kanamycin
FB
D4
E
9A
BC
5F
d Clarithromycin
25
74
DD
4
A
D4
E
9A
8D
BC
5F
74
DD
4
4
26537 Page 1 of 5
FE
9A
AB
8D
BC
45
D
B0
CD
9A
AB
8D
AB
DD
0
B4
BFC16B0AB48DABCDD9A45FE74D425FB7
6B
B0 AB A4 42 C1
AB 5F 5 6B
4
CD
D9 E 74
FB
7B 0A
6B 8D
0 A BC
A4 D4
25 FC B4
8D
AB 5F FB 16
4 8D
DD E7
4D 7B B0
A
AB
A 9A FC B4 CD
BC 4 5F 42
5F 16 8D D9
B4 E A4
17
16
15
14
13
12
11
DD 74 B7 B0 AB 10
8D 9A BF A CD 5F
A 4
D4 B4 E7
26537
BC 5F 25 C1
6 8 DA D9 4
DD E FB B0 A4 D4
is
74 7B 25
of
9A AB BC 5F
D4 FC E7 FB
AB 4 5F 25 16 48
D
DD
9A 4 7B
CD
D E74
FB B0 AB 45
D4
25 FC
9A D4 7B
FC A B4 CD FE FB 16
B0
4 5F 25 16 8D AB D9 74 7B
DD E74
FB B0 A 48 A4 D4
25 FC
9A B
7B A 5F F
BC DA 16
D4 FC 4 E7 B 7 B0 DD
infection caused by
45 25 16 8D 9A 4D BF AB BC
FE
74
FB
7 B A 45 42 C1 48 DD
D4 B FC
0A
B4
BC F 5 FB 6 D 9A
DD E7 7 B0 AB 45
25 8 B C
16
B D A 9 A 4D
F AB FE
FB
7B 0 B 45F 4 2 C 4 8
DD 74
AB 5F 16 9A
FC CD
D E 7 B 7 B 0
DA
B 4
D4
16 48 4 A 5 25
DA 9A
4
D4 BF
C B 4
CD FE
7
FB
B0 B 2 8 D
DA 9A D4 B4 FE FB
Page 2 of 5
4 FC
c
c
c
c
c
c
c
A4
d
b
d
b
d
b
d
b
d
b
d
b
d
b
DD E7 B7 B0 AB 2 48
9A 4D BF AB 5F 5F 16
42 C 4
CD
D E 7 B7 B 0
DA
45
FE 5F 16 8 DA 9A 4 D4 BF AB
74 B7 B0 B 4 5F 2 5F C 16 48
HIV
BF AB
HSV
CD DA
BFC16B0AB48DABCDD9A45FE74D425FB7
VZV
D4 E7 B0 H1N1
25 C1 48 D 4D
B7 BC
Sulfone
AB
pyridine
9A BF D
pyrazine
6B DA
linezolid
FB 42 48
45 C1
pyridazine
7B 0A 5 D
pyrimidine
BC F 6
cycloserine
Didanosine
Zidovudine
Delavirdine
Furosemide
Miconazole
Lamivudine
clindamycin
Itraconazole
FB
capreomycin
FC B4 DD E7 B0 AB
7
Sulfisoxazole
Ketoconazole
nitrofurantoin
Sulfanilamide
4 A
Sulfacetamide
B
Metronidazole
8D 9
Paper / Subject Code: 87611 / Medicinal Chemistry- III
16
without solvent
A4 D4 FC B4 CD
chloramphenicol
B0 AB
5F 2 5F 16 8 D9
Diloxanide furoate
AB B DA
48
CD
D E 7 B 7 0 B
A4
DA 9A 4 D4 BF A B4 CD
45 2 C 1 8
4
4D
Paper / Subject Code: 87611 / Medicinal Chemistry- III
BC
5F
D9
48
E7
A4
DA
CD
AB
4D
5F
D9
48
AB
B0
E7
A4
CD
AB
D
16
5F
D9
48
B
0
FC
A4
b Reagents and reactants are
DA
D
B
AB
16
BC
7B
D9
attached to a solid phase
8
B0
FC
B4
FB
DA
D
support
A
16
BC
B
9
A
25
c Reagents are used in the solid
DD
7
B0
C
B4
FB
DA
D4
BF
phase
BC
A
5
74
C1
48
B7
2
Molecules are constructed on a
0
d
A
D4
B
FE
BF
B
5F
D
16
solid phase support
0A
4
45
8
B7
2
7
FC
B4
18 Characteristic side effect associated with a phototoxicity
A
4
6B
FE
9A
5F
D
B
0A
Sparfloxacin is
1
5
DD
48
7
2
7
C
4
FB
D4
6B
FE
9A
b nephrotoxicity
BF
B
BC
0A
5
4
C1
45
DD
c hepatotoxicity
7
42
7
B
DA
6B
E
9A
F
4D
5F
d neurotoxicity
C
5F
1
48
AB
7
2
E7
C
A4
19 4-[(4-aminobenzene)sulfonyl]aniline is the a sulfanilamide
B
CD
D4
B
AB
F
5F
D
5F
16
7B
9
IUPAC name of
4
48
DD
B0
2
E7
FC
4
FB
DA
D4
b dapsone
9A
AB
16
7B
25
4
45
8
sulfacetamide
B
D
c
B0
FC
7
4
FB
DA
CD
D4
E
9A
AB
d sulfapyridine
16
5F
7B
25
74
8
AB
D
B0
FC
A4
4
FB
CD
D4
FE
B
8D
6
7B
9
b
A
Lanosterol-14-demethylase
25
C1
74
45
B
DD
0
B4
FB
DA
D4
FE
9A
Lanosterol-14-reductase
BF
16
BC
A
25
4
45
8
D
d Squalene dehydrogenase
7
0
E7
4
B
DA
D4
CD
6B
9A
F
AB
F
5F
B
25
4
48
AB
DD
7
B0
E7
C
A4
FB
D4
Q.II Attempt ANY TWO of the following. Draw structures wherever required. 20M
BF
AB
5F
8D
16
BC
D9
5
74
7
42
B0
FC
A4
Q1. B4
B
CD
DA
FE
4D
5F
16
B
D9
0A
45
AB
48
a. With reference to the structure, answer the following questions 4M
7
2
E7
C
B
CD
6B
9A
BF
AB
4D
5F
8D
5F
C1
AB
DD
B7
2
B0
E7
A4
B4
D4
BF
5F
8D
BC
16
D9
0A
4
45
B7
2
7
FC
B4
DA
CD
6B
D4
E
9A
5F
5F
7B
A
C1
4
8
AB
DD
B0
42
7
4
B4
FB
FE
A
4D
D
16
BC
9
A
25
5
48
DD
B0
FC
E7
4
A
D4
9A
AB
8D
16
BC
F
7B
B4
FB
CD
FE
9A
ii) Draw the structure of the salt form of the above drug.
8D
6
7B
A
5
C1
45
B
D
42
B0
4
FB
CD
iii)
9A
BF
D
16
A
25
DD
B7
B0
FC
DA
D4
5F
16
BC
7B
0A
74
48
42
FC
FB
DA
B
E
AB
4D
5F
16
7B
48
0
E7
FC
A4
FB
D4
c. Explain the structural modifications done to improve the acid stability and bioavailability
AB
5F
16
7B
25
74
of macrolides. 2M
B0
FC
A4
FB
D4
E
5F
16
B
D9
25
74
FC
4
FB
CD
D4
Q2.
E
9A
5F
7B
25
74
a. Explain the development of cephalosporins with the help of structural features. Comment
AB
DD
FB
D4
E
9A
5F
25
74
DD
D4
E
9A
8D
BC
5F
74
DD
4
4
26537 Page 3 of 5
FE
9A
AB
8D
BC
45
D
B0
CD
9A
AB
8D
AB
DD
0
B4
BFC16B0AB48DABCDD9A45FE74D425FB7
6B
E7
A4
DA
4
4D
Paper / Subject Code: 87611 / Medicinal Chemistry- III
BC
5F
D9
48
E7
A4
DA
CD
AB
4D
5F
D9
48
AB
B0
E7
A4
CD
AB
D
16
5F
D9
48
B
0
FC
A4
DA
D
B
AB
16
BC
7B
D9
c. What are bioprecursor prodrugs? 2M
8
B0
FC
B4
FB
DA
A
16
BC
B
9
A
25
Q. 3.
DD
7
B0
C
B4
FB
DA
D4
BF
a. With reference to the structure, answer the following questions 4M
BC
A
5
74
C1
48
B7
2
A
D4
B
FE
BF
B
5F
D
16
0A
4
45
8
B7
2
7
FC
B4
A
4
6B
FE
9A
5F
D
B
0A
4
1
5
DD
48
7
2
7
C
4
FB
D4
6B
FE
9A
BF
B
BC
0A
5
4
C1
45
DD
7
42
7
B
DA
6B
E
9A
F
4D
5F
C
5F
1
48
AB
7
2
E7
C
A4
B
CD
D4
B
AB
F
5F
i) Identify the chemical class and generic name of the drug.
D
5F
16
7B
9
4
48
DD
B0
2
E7
FC
4
ii) Classify the above drug based on its duration of ation.
FB
DA
D4
9A
AB
16
7B
iii) Draw the structure of any salt form of the drug.
25
4
45
8
D
B0
FC
7
4
FB
iv) What will happen if amide group of the drug is replaced by nitrile? DA
CD
D4
E
9A
AB
16
5F
7B
25
74
8
AB
D
B0
FC
A4
4
FB
CD
D4
FE
B
b. i) Explain the acid catalyzed degradation of cephalosporins with the help of suitable 8D
6
7B
9
A
25
C1
74
45
B
DD
reaction. 2M
0
B4
FB
DA
D4
FE
9A
BF
BC
A
25
4
45
8
D
7
0
E7
4
B
DA
D4
CD
6B
9A
F
AB
F
5F
48
AB
DD
7
B0
E7
C
A4
FB
D4
BF
AB
5F
8D
16
BC
D9
5
74
B0
FC
A4
B4
B
CD
DA
FE
4D
5F
16
B
D9
Q1. Give the synthetic scheme for synthesis of Isoniazid. Depict the metabolism of Isoniazid.
0A
45
AB
48
7
2
E7
C
B
CD
5M
6B
9A
BF
AB
4D
5F
8D
5F
Q2. With reference to the following scaffold, answer the following questions: 5M
C1
AB
DD
B7
2
B0
E7
A4
B4
D4
BF
5F
8D
BC
16
D9
0A
4
45
B7
2
7
FC
B4
DA
CD
6B
D4
E
9A
5F
5F
7B
A
C1
4
8
AB
DD
B0
42
7
4
B4
FB
FE
A
4D
D
16
BC
9
A
25
5
48
DD
B0
FC
E7
4
A
D4
9A
AB
8D
16
BC
F
7B
74
45
D
B0
FC
B4
FB
CD
FE
9A
8D
6
7B
A
5
C1
45
B
D
42
B0
4
FB
CD
9A
BF
D
16
A
25
DD
B7
B0
FC
DA
D4
5F
16
BC
7B
48
42
FC
FB
DA
Fluoro.
B
E
AB
4D
5F
16
7B
25
c) Highlight the part of the drug involved in binding to the target protein.
48
0
E7
FC
A4
FB
D4
d) Presence of small alkyl group at position 1 dictates the spectrum of activity. State whether
AB
5F
16
7B
25
74
FB
D4
E
5F
16
B
D9
25
74
FC
4
Q3. Explain with the help of suitable reactions the activation of acyclovir required for its
FB
CD
D4
E
9A
5F
7B
DD
FB
D4
E
9A
BC
5F
25
4
A
D4
E
9A
8D
BC
5F
74
DD
4
4
26537 Page 4 of 5
FE
9A
AB
8D
BC
45
D
B0
CD
9A
AB
8D
AB
DD
0
B4
BFC16B0AB48DABCDD9A45FE74D425FB7
6B
B0 AB A4 42 C1
AB 5F 5 6B
4
CD
D9 E 74
FB
7B 0A
6B 8D
0 A BC
A4 D4
25 FC B4
8D
AB 5F FB 16
4 8D
DD E7
4D 7B B0
A
AB
A 9A FC B4 CD
BC 4 5F 42
5F 16 8D D9
B4 DD E74 B7 B0 AB A4
8D 9A BF A CD 5F
A 4
D4 B4 E7
26537
C1 8 4
nucleus.
BC 5F 25 D9
DD E FB 6 B0 DA A4 D4
9A 74 7B AB BC 5F 25
D4 FC E7 FB
AB 4 5F 25 16 48
D
DD
9A 4 7B Drug
CD
D E74
FB B0 AB 45
D4
25 FC
9A D4 7B A CD FE FB 16
2. Sulfadiazine
4 FC B4 B0
1. Sulfapyridine
5F 25 16 AB 8D D9 74 7B
4. Sulfamethizole
E FB A D4 FC
b) Explain ADEPT.
B0 A4
3. Sulfamethizine
DD 48
Q5. Match the following:
74 7B A 5F BC 25 16
5. Sulfamethoxazole
9A D4 B F B
DA
45 FC
25 16 4 8D
E7
4D 7 B0
AB BC DD
FE FB B A 9A BF DD
74 7 45 42 C1 48
D4 B FC
0A
B4
BC F 5 FB 6 D 9A
DD E7 7 B0 AB 45
25 16 8D 9 4D B AB C
FB B A A 4 4 F C 4 DD FE
7B 0 AB B 5F 2 5F 16 8 9A 74
FC CD
D E 7 B 7 B 0
DA
B 4
D4
16 48 4 A 5 25
DA 9A
4
D4 BF
C B 4
CD FE
7
FB
B0
AB B 5 2 5F 1 8 D 9A 4 7B
CD FE B 6B DA D4 FC
D 7 0 B 2
b) Give the structure and use of Rimantadine.
48 4 7 A 45 5
Structure
DA 9A D4 B FC B4 C FE FB 16
Page 5 of 5
DD E7 B7 B0 AB A4
5F 42 FC 48
9A 4D BF AB 5F 16
42 C 4
CD
D E 7 B7 B 0
DA
45
FE 5F 16 8 DA 9A 4 D4 BF AB
BFC16B0AB48DABCDD9A45FE74D425FB7
D4 E7 B0
25 C1 48 D 9A 4D
B7
BF AB BC
FB 6B DA
45 42 C1 48 D
7B
FC
0A
B4
BC F 5 FB 6 D
DD E7 7 B0 AB
4 A
ii)Pyridine
8D 9 B
Paper / Subject Code: 87611 / Medicinal Chemistry- III
16 CD
iv)Isoxazole
A4 D4 FC B4
B0
AB
AB
5F 2 5F 16 8 D9
48
CD
D E 7 B 7 B 0
DA
B
A4
DA 9A 4 D4 BF A B4 CD
C
iii) 1,3,4-thiadiazole
BC 45 2 5F 1 8 D9
DD FE B 6B DA
Q6. a) Give the structure, generic name and use of drug containing 1,4-naphtho quinone
A4
74 7B 0A BC 5F
9A F B
i)Unsubsituted Pyrimidine
D4 D
Heterocyclic ring present
v) 4,6-dimethyl pyrimidine
E7
Q.8. Name two computer aided drug design techniques. Explain molecular docking in detail.
Q.9 What is solid phase synthesis? Elaborate on the linkers used in solid phase synthesis.5M
45 C1 48
5M
2M
3M
2M
5M
2M
25
3M
D9
FE FB 6B DA A4
74 7B 0A BC 5F
D4 F C B4 D E7
25 1 6B 8D D9 4D
FB
7B 0A A BC
A4 4
5F
FC B 48 DD E7
16
B D A 9A 4D